Osteoarthritis Drugs Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-17　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 8.45 Bn
2033 年預估規模: USD 17.75 Bn
年複合成長率 CAGR: 11.2%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-17頁數 152報告編號 CMI2580

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Osteoarthritis Drugs Market, By Drug Class (Analgesics, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Hyaluronic Acid, Phase III Drugs), By Route of Administration (Oral, Parenteral, Topical), By Disease Type (Ankle Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, Others (Spinal Osteoarthritis and Cervical Osteoarthritis)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

報告摘要

Osteoporosis is a systemic disorder characterized by decreased bone mass and microarchitectural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures of the hip, spine, and wrist. Due to its important prevalence worldwide, osteoporosis is considered a serious public health concern associated with disability and pain. The pathophysiology of osteoporosis is an imbalance between bone resorption and bone formation. In osteoporosis, bone resorption takes place to a greater extent than bone formation, so a negative balance occurs with a net loss of bone and an accompanying increasing risk of fractures, resulting in deformity and chronic pain. Nociceptive pain is considered to be chronic when it has been present for at least 3 months. • The imbalance between bone formation and bone resorption might occur as a result of one or a combination of the following factors: • Increased bone resorption within a remodeling unit. • Decreased bone formation within a remodeling unit (incomplete coupling) Market Dynamics Key players in the market are focused on organic growth strategies such as acquisitions, which is expected to drive the global osteoarthritis drugs market growth over the forecast period. For instance, on August 15, 2022, Gurnet Point Capital, an investment service company and Patient Square Capital, a healthcare investment company, announced the completion of their acquisition of Radius Health, Inc., a Biotechnology Company. Radius’ lead product, TYMLOS (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. This acquisition will help the company in further expansion in the osteoarthritis drugs market over the forecast period. However, use of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen in pain management of osteoarthritis can cause cardiovascular diseases, which in turn is expected to hinder the market growth. For instance, in June 2018, the European League against Rheumatism (EULAR) stated the risk of cardiovascular diseases with the regular use of NSAIDs in the treatment of osteoarthritis pain. Key features of the study • This report provides an in-depth analysis of the global osteoarthritis drugs market, market size (USD Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025 as the base year • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players • It profiles key players in the global osteoarthritis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies • Key players covered as a part of this study include Pfizer, Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Therapeutics plc, Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Sanofi, Regeneron, GlaxoSmithKline Plc., Johnson & Johnson Private Limited, Bayer AG, Novartis AG, Ferring B.V., Pacira Pharmaceuticals, Inc, Zimmer Biomet, OrthogenRx, Inc. and PHARMED LTD. • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future drug launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics • The global osteoarthritis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoarthritis drugs market Market Segmentation • Drug Class Insights (Revenue, USD Bn, 2026 - 2033) o Analgesics o Non-steroidal Anti-Inflammatory Drugs o Corticosteroids o Hyaluronic Acid o Phase III Drugs • Route of Administration Insights (Revenue, USD Bn, 2026 - 2033) o Oral o Parenteral o Topical • Disease Type Insights (Revenue, USD Bn, 2026 - 2033) o Ankle Osteoarthritis o Hip Osteoarthritis o Knee Osteoarthritis o Shoulder Osteoarthritis o Others (Spinal Osteoarthritis and Cervical Osteoarthritis) • Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Bn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  North Africa  Central Africa  South Africa • Key Players Insights o Pfizer, Inc. o Abbott o Eli Lilly and Company o ABIOGEN PHARMA S.p.A o Horizon Therapeutics plc o Ferring B.V. o Merck Sharp & Dohme Corp. o Medivir o Bioventus o Sanofi o Regeneron o GlaxoSmithKline Plc. o Johnson & Johnson Private Limited o Bayer AG o Novartis AG o Ferring B.V. o Pacira Pharmaceuticals, Inc o Zimmer Biomet o OrthogenRx, Inc. o PHARMED LTD

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Global Osteoarthritis Drugs Market, By Drug Class  Global Osteoarthritis Drugs Market, By Route of Administration  Global Osteoarthritis Drugs Market, By Disease Type  Global Osteoarthritis Drugs Market, By Distribution Channel  Global Osteoarthritis Drugs Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trend 4. Global Osteoarthritis Drugs Market, By Drug Class, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Analgesics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Non-steroidal Anti-Inflammatory Drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Corticosteroids  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Hyaluronic Acid  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Phase III Drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 5. Global Osteoarthritis Drugs Market, By Route of Administration, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Oral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Parenteral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Topical  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 6. Global Osteoarthritis Drugs Market, By Disease Type, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Ankle Osteoarthritis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Hip Osteoarthritis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Knee Osteoarthritis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Shoulder Osteoarthritis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Others (Spinal Osteoarthritis and Cervical Osteoarthritis)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 7. Global Osteoarthritis Drugs Market, By Distribution Channel, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 8. Global Osteoarthritis Drugs Market, By Region, 2020 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Value (USD Bn)  Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Value (USD Bn)  Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Value (USD Bn)  Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Value (USD Bn)  Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Value (USD Bn)  Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 9. Competitive Landscape o Pfizer, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Abbott  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Eli Lilly and Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o ABIOGEN PHARMA S.p.A  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Horizon Therapeutics plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Ferring B.V.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck Sharp & Dohme Corp.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Medivir  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bioventus  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sanofi  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Regeneron  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o GlaxoSmithKline Plc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Johnson & Johnson Private Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bayer AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Ferring B.V.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pacira Pharmaceuticals, Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Zimmer Biomet  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o OrthogenRx, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o PHARMED LTD  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 10. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 11. References and Research Methodology o References o Research Methodology o About us

提及公司

Pfizer, Inc.AbbottEli Lilly and CompanyABIOGEN PHARMA S.p.AHorizon Therapeutics plcFerring B.V.Merck Sharp & Dohme Corp.MedivirBioventusSanofiRegeneronGlaxoSmithKline Plc.Johnson & Johnson Private LimitedBayer AGNovartis AGFerring B.V.Pacira Pharmaceuticals, IncZimmer BiometOrthogenRx, Inc.PHARMED LTD

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們